26.25  0.37 (1.43%)		08-07 16:00
Open: 26.2 High: 26.335 Volume: 1,990,980		Pre. Close: 25.88 Low: 25.25 Market Cap: 4,902(M)

Short term
Mid term
Targets	6-month :	31.64	1-year :	36.95
Resists	First :	27.09	Second :	31.64
Pivot price	25.05
Supports	First :	23.49	Second :	21.28
MAs	MA(5) :	25.9	MA(20) :	24.68
	MA(100) :	20.07	MA(250) :	18.15
MACD	MACD :	1.1	Signal :	1.1
%K %D	K(14,3) :	82	D(3) :	84.4
RSI	RSI(14): 65.5
52-week	High :	27.09	Low :	10.77

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DYN ] has closed below upper band by 20.2%. Bollinger Bands are 6.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	26.65 - 26.78	26.78 - 26.89
Low:	25.27 - 25.41	25.41 - 25.52
Close:	25.66 - 25.89	25.89 - 26.07

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Thu, 06 Aug 2026
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView

Thu, 06 Aug 2026
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - Stock Titan

Tue, 04 Aug 2026
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews

Fri, 31 Jul 2026
Dyne Therapeutics, Inc. $DYN Shares Sold by Vivo Capital LLC - MarketBeat

Wed, 29 Jul 2026
Dyne raises $431M as FDA reviews Duchenne muscular dystrophy drug - Stock Titan

Thu, 23 Jul 2026
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	165 (M)
Shares Float	165 (M)
Held by Insiders	0.2 (%)
Held by Institutions	104 (%)
Shares Short	21,490 (K)
Shares Short P.Month	22,810 (K)

EPS	-3.16
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.8 %
Return on Equity (ttm)	-58.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.84
Qtrly Earnings Growth	0 %
Operating Cash Flow	-442 (M)
Levered Free Cash Flow	-292 (M)

PE Ratio	-8.34
PEG Ratio	0
Price to Book value	5
Price to Sales	0
Price to Cash Flow	-9.82

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.